KR20150142691A - 테트란드린 패밀리 제약 제제 및 방법 - Google Patents

테트란드린 패밀리 제약 제제 및 방법 Download PDF

Info

Publication number
KR20150142691A
KR20150142691A KR1020157029740A KR20157029740A KR20150142691A KR 20150142691 A KR20150142691 A KR 20150142691A KR 1020157029740 A KR1020157029740 A KR 1020157029740A KR 20157029740 A KR20157029740 A KR 20157029740A KR 20150142691 A KR20150142691 A KR 20150142691A
Authority
KR
South Korea
Prior art keywords
family member
pharmaceutical
family
formula
disodium salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020157029740A
Other languages
English (en)
Korean (ko)
Inventor
론 디. 캐롤
Original Assignee
씨비에이 파마, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 씨비에이 파마, 인크. filed Critical 씨비에이 파마, 인크.
Publication of KR20150142691A publication Critical patent/KR20150142691A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020157029740A 2013-03-15 2014-03-06 테트란드린 패밀리 제약 제제 및 방법 Ceased KR20150142691A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361792849P 2013-03-15 2013-03-15
US61/792,849 2013-03-15
PCT/US2014/021195 WO2014149848A1 (en) 2013-03-15 2014-03-06 Tetrandrine family pharmaceutical formulations and method

Publications (1)

Publication Number Publication Date
KR20150142691A true KR20150142691A (ko) 2015-12-22

Family

ID=51529969

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157029740A Ceased KR20150142691A (ko) 2013-03-15 2014-03-06 테트란드린 패밀리 제약 제제 및 방법

Country Status (7)

Country Link
US (4) US9517234B2 (https=)
EP (1) EP2968310A4 (https=)
JP (1) JP2016512818A (https=)
KR (1) KR20150142691A (https=)
CN (1) CN105358149A (https=)
MX (1) MX2015013155A (https=)
WO (1) WO2014149848A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10576077B2 (en) 2015-03-23 2020-03-03 Southwest Research Institute Pharmaceutical salt forms of Cepharanthine and Tetrandrine
CN107260694A (zh) * 2017-06-14 2017-10-20 广西大海阳光药业有限公司 一种治疗硅肺、风湿痛、关节痛及神经痛的长效新制剂
CN112402419B (zh) * 2019-08-23 2023-12-08 华东理工大学 海兰地嗪或其药学上可接受的盐在糖尿病或糖尿病并发症药物中的应用
CN111675717B (zh) * 2020-06-21 2023-04-07 兰州理工大学 粉防己单体化合物及其提取方法和用途
US20230338362A1 (en) * 2020-09-17 2023-10-26 Iaterion, Inc. Methods and compositions for treating viral infections
CN113456643B (zh) * 2021-08-11 2022-04-01 遵义医科大学 一种含普那布林的药物组合及其应用
CN114159438B (zh) * 2021-11-30 2023-07-18 首都医科大学附属北京安定医院 海兰地嗪及其衍生物在制备治疗抑郁症药物中的应用及所制备的抗抑郁药物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4569852A (en) * 1983-08-23 1986-02-11 Warner-Lambert Company Maintenance of flavor intensity in pressed tablets
JPH0678232B2 (ja) * 1986-03-07 1994-10-05 株式会社ツムラ アンジオテンシンｉ転換酵素阻害剤
JPH0678231B2 (ja) * 1986-03-08 1994-10-05 株式会社ツムラ 血液粘度低下剤
JPH0733388B2 (ja) * 1987-01-22 1995-04-12 株式会社ツムラ 新規アルカロイド
JPH02243627A (ja) * 1989-03-16 1990-09-27 Tsumura & Co 狭心症治療薬
US6911454B1 (en) 1989-09-28 2005-06-28 Cancer Biologics Of America, Inc. Method for potentiating primary drugs in treating multidrug resistant disease
US5025020A (en) 1989-09-28 1991-06-18 Cancer Biologics Of America, Inc. Use of tetrandrine and its derivatives to treat malaria
US5332747A (en) 1989-09-28 1994-07-26 Cancer Biologics Of America, Inc. Method for potentiating primary drugs in treating multidrug resistant parasitic disease cells
JPH0499723A (ja) * 1990-08-17 1992-03-31 Kaken Shiyouyaku Kk ウイルス・ゲノム不活化剤
US5192802A (en) 1991-09-25 1993-03-09 Mcneil-Ppc, Inc. Bioadhesive pharmaceutical carrier
US5627195A (en) * 1995-04-11 1997-05-06 Massachusetts Eye And Ear Infirmary Treatment for ocular inflammation
US6218541B1 (en) * 1999-06-28 2001-04-17 Cba, International, Inc. Method for extracting bisbenzylisoquinolines
ATE283048T1 (de) * 1999-12-08 2004-12-15 Pharmacia Corp Cyclooxygenase-2 hemmer enthaltende zusammensetzungen mit schnellem wirkungseintritt
US20050245559A1 (en) * 2004-01-23 2005-11-03 Koul Hari K Treatment and prevention of prostate cancer
EP2069021A2 (en) * 2006-08-04 2009-06-17 AGI Therapeutics Research Limited Methods for treating at least one condition having mt1 receptor, 5ht2b receptor, and l-type calcium channel activity
JP2011512416A (ja) * 2008-02-20 2011-04-21 ザ・キュレイターズ・オブ・ザ・ユニバーシティー・オブ・ミズーリ オメプラゾール及びランソプラゾールの組合せと緩衝剤を含んでなる組成物とそれを使用する方法
EP2241561A1 (en) 2009-04-16 2010-10-20 Neuron Biopharma, S.A. Neuroprotective, hypocholesterolemic and antiepileptic compound
US8609844B2 (en) 2009-11-05 2013-12-17 Cba Pharma, Inc. Method for extracting and purifying bisbenzylisoquinolines
EP2491930A1 (en) * 2011-02-25 2012-08-29 Deva Holding Anonim Sirketi Pharmaceutical combination of betahistine and trimetazidine
JP2015531785A (ja) * 2012-09-13 2015-11-05 シービーエー・ファーマ・インコーポレイテッドＣｂａ Ｐｈａｒｍａ，Ｉｎｃ． テトランドリン医薬製剤及び方法
CN102898433B (zh) * 2012-09-26 2015-04-15 中国医药研究开发中心有限公司 一种汉防己甲素的没食子酸盐、其药物组合物、其制备方法及其用途
WO2014048377A1 (zh) * 2012-09-28 2014-04-03 杭州本生药业有限公司 治疗肿瘤的组合药物及其应用

Also Published As

Publication number Publication date
MX2015013155A (es) 2016-04-04
EP2968310A4 (en) 2017-01-11
US10023584B2 (en) 2018-07-17
CN105358149A (zh) 2016-02-24
US9517234B2 (en) 2016-12-13
EP2968310A1 (en) 2016-01-20
US10815243B2 (en) 2020-10-27
US20170050976A1 (en) 2017-02-23
JP2016512818A (ja) 2016-05-09
WO2014149848A1 (en) 2014-09-25
US20180298022A1 (en) 2018-10-18
US20170050975A1 (en) 2017-02-23
US20140275137A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
KR20150142691A (ko) 테트란드린 패밀리 제약 제제 및 방법
TWI844786B (zh) 一種藥物組合物及其應用
CN115192558B (zh) 一种环状酮类化合物的用途
RU2668882C2 (ru) Жидкая фармацевтическая композиция
BRPI0912112B1 (pt) composição farmacêutica compreendendo composto tendo atividade antagonística em receptor de adenosina a2a útil em suprimir tolerância analgésica
HRP20170564T1 (hr) Derivati aminociklobutana, metoda njihove priprave i njihova upotreba za lijekove
CN111233878B (zh) 一种加兰他敏双羟萘酸盐及其制备方法
US20140073591A1 (en) Mdr method and products for treating mrsa
CN104955330A (zh) 粉防己碱药物制剂及方法
WO2007143895A1 (fr) Solution supersaturée de chlorhydrate de gemcitabine et son procédé de préparation
JP2025011312A (ja) ｐ－ボロノフェニルアラニンを含有する注射液剤の析出防止方法
JP2025015727A (ja) ｐ－ボロノフェニルアラニンを含有する注射液剤
RU2745985C1 (ru) Антикоронавирусный терапевтический агент - замещенный 7-гидрокси-3,4,12,12а-тетрагидро-1H-[1,4]оксазино[3,4-c]пиридо[2,1-f][1,2,4]триазин-6,8-дион для профилактики и лечения COVID-19
CN111233877B (zh) 一种加兰他敏帕莫酸盐及其制备方法
CN102302495A (zh) 一种供注射用盐酸托烷司琼药物组合物
CN116157127A (zh) 化合物用于治疗口干燥症的用途
KR20150143504A (ko) 약물 및 영양 보조식품의 생체이용률을 증진시키기 위한 방법 및 생성물
US6784315B2 (en) Stilbene derivative crystal and method for producing the same
US20140275138A1 (en) Method and products for treating diabetes
RU2851166C1 (ru) Фармацевтическая композиция и ее применение
US20240382507A1 (en) Pharmaceutical compositions comprising 2,3,4,5- tetrahydrobenzothiepin- 1,1-dioxide derivatives and the use thereof
CN102920716B (zh) 复方抗球虫药物磺胺氯吡嗪钠溶液的制备方法
JP2016514143A (ja) 薬物及び栄養補助剤の細胞取り込みを高める方法及び生成物
HK40063844A (en) Pharmaceutical composition and use thereof
HK40085950A (en) Compound for use in the treatment of dry mouth

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20151015

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190228

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200601

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20210401

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200601

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I